1. In vivoprooxidant state in Werner syndrome (WS): Results from three WS patients and two WS heterozygotes
- Author
-
Christina Dunster, Emilia Vuttariello, Paolo Degan, Ana Lloret, Giovanni Pagano, Marco d'Ischia, Rita Calzone, Frank J. Kelly, Aldo Giudice, Michel Warnau, Yurdanur Kilinç, Paola Manini, Roberta Masella, Giuseppe Castello, Adriana Zatterale, and Federico V. Pallardó
- Subjects
Adult ,Male ,Heterozygote ,medicine.medical_specialty ,Dinoprost ,medicine.disease_cause ,Biochemistry ,Antioxidants ,chemistry.chemical_compound ,In vivo ,Internal medicine ,Leukocytes ,medicine ,Humans ,Deoxyguanosine ,Chromatography, High Pressure Liquid ,Methylglyoxal ,8-Hydroxy-2'-deoxyguanosine ,Glyoxal ,General Medicine ,Glutathione ,Middle Aged ,Pyruvaldehyde ,Ascorbic acid ,Endocrinology ,chemistry ,8-Hydroxy-2'-Deoxyguanosine ,Uric acid ,Female ,Werner Syndrome ,Oxidation-Reduction ,Oxidative stress - Abstract
The hypothesis was tested that Werner syndrome (WS) phenotype might be associated with an in vivo prooxidant state. A set of redox-related endpoints were measured in three WS patients, two of their parents, and 99 controls within a study of some cancer-prone and/or ageing-related genetic disorders. The following analytes were measured: (a) leukocyte 8-hydroxy-2'-deoxyguanosine; (b) glutathione from whole blood, and (c) plasma levels of glyoxal, methylglyoxal, 8-isoprostane, and some plasma antioxidants (uric acid, ascorbic acid, alpha- and gamma-tocopherol). Leukocyte 8-hydroxy-2'-deoxyguanosine levels showed a significant increase in the 3 WS patients vs. 85 controls (p
- Published
- 2005
- Full Text
- View/download PDF